Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation.

Leukemia & lymphoma - 1 Nov 2018

Takei Tomomi, Yokoyama Kazuaki, Shimizu Eigo, Konuma Takaaki, Takahashi Satoshi, Yamaguchi Rui, Imoto Seiya, Miyano Satoru, Tojo Arinobu

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Azacitidine
Share to Cord Blood Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Share to Neoplasm Recurrence, Local

Share to Neoplasms, Second Primary

Share to Salvage Therapy

Source

Identifiers

PMID: 29648492
DOI: 10.1080/10428194.2018.1443335

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation.PMID 29648492Read ↗

Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapySemantic proximity Read ↗

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.Semantic proximity Read ↗

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation.Semantic proximity Read ↗

AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.Semantic proximity Read ↗

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantationSemantic proximity Read ↗

A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemiaSemantic proximity Read ↗

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.Semantic proximity Read ↗

Preexisting TP53 mutation in therapy-related acute myeloid leukemia.Semantic proximity Read ↗

Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasiaSemantic proximity Read ↗

Characterization of a novel TPMT mutation associated with azathioprine-induced myelosuppression.Semantic proximity Read ↗

5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.